Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study

Bone Marrow Transplantation

Volumn 46, Issue 12, 2011, Pages 1551-1556

  Lam, D C L ^a   Lam, B ^a   Wong, M K Y ^a   Lu, C ^a   Au, W Y ^a   Tse, E W C ^a   Leung, A Y H ^a   Kwong, Y L ^a   Liang, R H S ^a   Lam, W K ^a   Ip, M S M ^a   Lie, A K W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Azithromycin; Bronchiolitis obliterans syndrome (BOS); Hematopoietic SCT (HSCT)

Indexed keywords

AZITHROMYCIN; PLACEBO;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRONCHIOLITIS OBLITERANS; BRONCHOSPIROGRAPHY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FORCED EXPIRATORY VOLUME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; SYNDROME; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856096516     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.1     Document Type: Article

References (28)

1. Soubani AO, Uberti JP. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J 2007; 29: 1007-1019. (Pubitemid 46711908)
2. Dudek AZ, Mahaseth H. Hematopoietic stem cell transplantrelated airflow obstruction. Curr Opin Oncol 2006; 18: 115-119. (Pubitemid 43740429)
3. Watkins TR, Chien JW, Crawford SW. Graft versus hostassociated pulmonary disease and other idiopathic pulmonary complications after hematopoietic stem cell transplant. Semin Respir Crit Care Med 2005; 26: 482-489. (Pubitemid 41552377)
4. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302: 306-314.
5. Verleden GM, Dupont LJ, Van Raemdonck DE. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur Respir J 2005; 25: 221-224. (Pubitemid 40246520)
6. Grossman EJ, Shilling RA. Bronchiolitis obliterans in lung transplantation: the good, the bad, and the future. Transl Res 2009; 153: 153-165.
7. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310. (Pubitemid 34224094)
8. Hopkins PM, Aboyoun CL, Chhajed PN, Malouf MA, Plit ML, Rainer SP et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004; 170: 1022-1026. (Pubitemid 39425700)
9. Crawford SW, Clark JG. Bronchiolitis associated with bone marrow transplantation. Clin Chest Med 1993; 14: 741-749. (Pubitemid 23358013)
10. Fietta AM, Meloni F. Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. Curr Med Chem 2008; 15: 716-723. (Pubitemid 351516807)
11. Shitrit D, Bendayan D, Gidon S, SauteM, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005; 24: 1440-1443. (Pubitemid 41247833)
12. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172: 772-775. (Pubitemid 41324235)
13. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121-125. (Pubitemid 37046642)
14. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36-41.
15. Porhownik NR, Batobara W, Kepron W, Unruh HW, Bshouty Z. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J 2008; 15: 199-202.
16. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005; 25: 490-493. (Pubitemid 40340107)
17. Maimon N, Lipton JH, Chan CK, Marras TK. Macrolides in the treatment of bronchiolitis obliterans in allograft recipients. Bone Marrow Transplant 2009; 44: 69-73.
18. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versushost disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
19. Ip MS, Ko FW, Lau AC, Yu WC, Tang KS, Choo K et al. Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest 2006; 129: 384-392. (Pubitemid 43289859)
20. Chan SL, Chan-Yeung MM, Ooi GC, Lam CL, Cheung TF, Lam WK et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis. Chest 2002; 122: 2030-2037. (Pubitemid 36051140)
21. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414. (Pubitemid 34761100)
22. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566-570. (Pubitemid 44330550)
23. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54: 21-28. (Pubitemid 39028963)
24. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77: 1465-1467. (Pubitemid 38668447)
25. Santo Tomas LH, Loberiza Jr FR, Klein JP, Layde PM, Lipchik RJ, Rizzo JD et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153-161. (Pubitemid 40994467)
26. O0Brien KD, Hackman RC, Sale GE, Prentice R, Deeg J, Thomas ED et al. Lymphocytic bronchitis unrelated to acute graft-versus-host disease in canine marrow graft recipients. Transplantation 1984; 37: 233-238. (Pubitemid 14164933)
27. Taylor PM, Rose ML, Yacoub MH. Expression of MHC antigens in normal human lungs and transplanted lungs with obliterative bronchiolitis. Transplantation 1989; 48: 506-510. (Pubitemid 19236522)
28. Hodge G, Hodge S, Chambers D, Reynolds PN, Holmes M. Bronchiolitis obliterans syndrome is associated with absence of suppression of peripheral blood Th1 proinflammatory cytokines. Transplantation 2009; 88: 211-218.